Trigeminal‐Targeted Treatments in Migraine: Is 60% the Magic Number?

Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class

(2019) Richard Hargreaves et al.   HEADACHE

Targeted 5-HT1F Therapies for Migraine

(2018) Marta Vila-Pueyo   Neurotherapeutics

Pharmacotherapy for acute migraines in children and adolescents

(2018) P. Barbanti et al.   EXPERT OPINION ON PHARMACOTHERAPY

Human models of migraine — short-term pain for long-term gain

(2017) Messoud Ashina et al.   Nature Reviews Neurology

Pathophysiology of Migraine: A Disorder of Sensory Processing

(2017) Peter J. Goadsby et al.   PHYSIOLOGICAL REVIEWS

Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations

(2017) Piero Barbanti et al.   Journal of Pain Research

Are migraine endophenotypes needed?

(2016) Jes Olesen   Nature Reviews Neurology

CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment

(2015) Lars Edvinsson   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis

(2015) Chris Cameron et al.   HEADACHE

Efficacy, Safety, and Tolerability of Telcagepant in the Treatment of Acute Migraine: A meta-Analysis

(2013) Xiao-ping Cui et al.   Pain Practice

Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial

(2012) Piero Barbanti et al.   JOURNAL OF HEADACHE AND PAIN

Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine

(2011) David J Hewitt et al.   CEPHALALGIA

BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: Results from a phase II study

(2010) Hans-Christoph Diener et al.   CEPHALALGIA

PACAP38 induces migraine-like attacks in patients with migraine without aura

(2008) Henrik Winther Schytz et al.   BRAIN